Gaurav Munj 2022-03-04T06:42:16+00:00 Press Releases Site - Investor Relations Nav Overview Press Releases Events and Presentations Financial Filings Stock Information Corporate Governance Contact Upcoming and Recent Events Corporate Presentation SEC Filings Stock Quote & Chart Governance Documents Committees Year None20232022 December 1, 2023 Biohaven Presents Expanded EEG and Safety Data for BHV-7000 at the American Epilepsy Society Annual Meeting November 14, 2023 Biohaven Reports Third Quarter 2023 Financial Results and Recent Business Developments October 16, 2023 Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek® October 5, 2023 Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares October 2, 2023 Biohaven Announces Pricing of $225 Million Public Offering of Common Shares October 2, 2023 BIOHAVEN ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES September 14, 2023 Biohaven Completes Enrollment in Pivotal Phase 3 Study of Taldefgrobep Alfa in Spinal Muscular Atrophy September 5, 2023 Biohaven Announces Positive Data from its Exploratory Electroencephalogram (EEG) Biomarker Study of BHV-7000, Completion of Once-Daily Formulation Development, and Plan to Initiate Phase 3 Pivotal Studies July 31, 2023 Biohaven's Taldefgrobep Alfa Receives EU Orphan Drug Designation for Spinal Muscular Atrophy July 31, 2023 Biohaven Reports Second Quarter 2023 Financial Results and Recent Business Developments Current page 1 Page 2 ► ► Displaying 1 - 10 of 20 BIOHAVEN (BHVN) Volume Market Cap 52 Week High 52 Week Low Data Provided by Refinitiv. Minimum 15 minutes delayed.
Year None20232022 December 1, 2023 Biohaven Presents Expanded EEG and Safety Data for BHV-7000 at the American Epilepsy Society Annual Meeting November 14, 2023 Biohaven Reports Third Quarter 2023 Financial Results and Recent Business Developments October 16, 2023 Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek® October 5, 2023 Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares October 2, 2023 Biohaven Announces Pricing of $225 Million Public Offering of Common Shares October 2, 2023 BIOHAVEN ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES September 14, 2023 Biohaven Completes Enrollment in Pivotal Phase 3 Study of Taldefgrobep Alfa in Spinal Muscular Atrophy September 5, 2023 Biohaven Announces Positive Data from its Exploratory Electroencephalogram (EEG) Biomarker Study of BHV-7000, Completion of Once-Daily Formulation Development, and Plan to Initiate Phase 3 Pivotal Studies July 31, 2023 Biohaven's Taldefgrobep Alfa Receives EU Orphan Drug Designation for Spinal Muscular Atrophy July 31, 2023 Biohaven Reports Second Quarter 2023 Financial Results and Recent Business Developments Current page 1 Page 2 ► ► Displaying 1 - 10 of 20
December 1, 2023 Biohaven Presents Expanded EEG and Safety Data for BHV-7000 at the American Epilepsy Society Annual Meeting
November 14, 2023 Biohaven Reports Third Quarter 2023 Financial Results and Recent Business Developments
October 16, 2023 Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek®
October 5, 2023 Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
September 14, 2023 Biohaven Completes Enrollment in Pivotal Phase 3 Study of Taldefgrobep Alfa in Spinal Muscular Atrophy
September 5, 2023 Biohaven Announces Positive Data from its Exploratory Electroencephalogram (EEG) Biomarker Study of BHV-7000, Completion of Once-Daily Formulation Development, and Plan to Initiate Phase 3 Pivotal Studies
July 31, 2023 Biohaven's Taldefgrobep Alfa Receives EU Orphan Drug Designation for Spinal Muscular Atrophy
July 31, 2023 Biohaven Reports Second Quarter 2023 Financial Results and Recent Business Developments
